Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBER: Azithromycin to Modify Bronchiectasis Exacerbation Risk
NCT07608328Phase 4Recruiting
- Sponsor
- Assiut University
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Non-cystic fibrosis bronchiectasis (NCFB) comparing Experimental Azithromycin Arm with Placebo Control Arm (2 arms). Primary endpoint: Occurrence of at Least One Bronchiectasis Exacerbation at 12 months. Started Jun 2026; status: recruiting.
02
Drugs
azithromycin
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT07608328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07608328.